A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeLivnat Jerby‐Arnon, Charles H. Yoon, Shu Wang et al.|Cell|2018Cited by 1.5k
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Matteo S. Carlino et al.|The Lancet|2024Cited by 729
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersDouglas B. Johnson, Joseph I. Clark, Ryan J. Sullivan et al.|JAMA Oncology|2015Cited by 656
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Jeffrey R. Infante et al.|Cancer Discovery|2017Cited by 418
Exploring the Feasibility of a Mindfulness-Music Therapy Intervention to Improve Anxiety and Stress in Adolescents and Young Adults with CancerRobert Knoerl, Jennifer A. Ligibel, Emanuele Mazzola et al.|Journal of Pain and Symptom Management|2021Cited by 50